Par Pharma (PRX) Enters Agreement with sanofi-aventis (SNY) to Settle Patent Litigation Over Generic Eloxatin(R)
Tweet Send to a Friend
Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it (and its subsidiary Par Pharmaceutical and development partner MN Pharmaceuticals ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
